CML patients who have high expression of the T-cell inhibitory receptor (CTLA-4)-ligand CD86 on plasmacytoid dendritic cells have a higher risk of relapsing after discontinuing therapy with a tyrosine kinase inhibitor. (Source: CancerNetwork)
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kpQ1Xd
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Shehwaz Anwar, Hina Youn...
-
Abstract Maternal obesity is associated with large-for-gestational-age (LGA) neonates and programming of obesity-related cardiovascular d...
-
Publication date: 20 March 2017 Source: Gene, Volume 605 Author(s): Hicham El Hadi, Imane Abdellaoui-Maane, Denise Kottwitz, Manal El Amra...
-
Gentle Sunder Shrestha, Bishesh Sharma Poudyal, Gopal Sedain, Khandokar Imran Mahmud, Niranja Acharya Indian Journal of Critical Care Medi...
-
RT @ecancer_espanol : Comienza nuestro taller en radioterapia https://t.co/ws2OfqSKs4 https://t.co/4EINTKfOI4 from #AlexandrosSfakianaki...
-
IJERPH, Vol. 15, Pages 15: Child Nutritional Status in the Changing Socioeconomic Region of the Northern Amazon, Brazil International Journ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου